What one share of Brainstorm Cell Therapeutics holds
Brainstorm Cell Therapeutics Inc. is a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”, also known as Lou Gehrig’s disease), progressive multiple sclerosis (“PMS”), Alzheimer’s disease (“AD”), and other neurodegenerative diseases.
Brainstorm Cell Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.95 |
|---|---|
| Cash and investments | $0.00 |
| Book value | −$1.05 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2011 | — | −$7.34 | $0.09 | −$4.25 | — | $2.65 |
| 2012 | — | −$5.61 | $0.15 | −$4.95 | — | $5.97 |
| 2013 | — | −$6.84 | $0.15 | −$5.81 | — | $3.50 |
| 2014 | — | −$10.15 | $0.18 | −$5.10 | — | $6.55 |
| 2015 | — | −$6.92 | $0.04 | −$6.07 | — | $11.37 |
| 2016 | — | −$4.00 | $0.08 | −$4.79 | — | $7.95 |
| 2017 | — | −$3.96 | $0.14 | −$2.03 | — | $4.65 |
| 2018 | — | −$10.46 | $0.28 | −$9.57 | — | $3.62 |
| 2019 | — | −$15.92 | $0.32 | −$8.03 | — | −$7.91 |
| 2020 | — | −$15.99 | $0.19 | −$17.88 | — | $15.13 |
| 2021 | — | −$10.14 | $0.14 | −$11.03 | — | $7.97 |
| 2022 | — | −$9.97 | $0.01 | −$7.95 | — | −$1.23 |
| 2023 | — | −$5.99 | $0.01 | −$7.13 | — | −$1.20 |
| 2024 | — | −$2.31 | — | — | — | −$1.26 |
| 2025 | — | −$1.11 | — | — | — | −$0.90 |
Common questions about Brainstorm Cell Therapeutics
How much does one share of Brainstorm Cell Therapeutics earn?
Over the last 12 months, Brainstorm Cell Therapeutics lost $0.95 for each share.
Does Brainstorm Cell Therapeutics pay a dividend?
Brainstorm Cell Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Brainstorm Cell Therapeutics’s book value per share?
Brainstorm Cell Therapeutics’s book value is negative (−$1.05 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Brainstorm Cell Therapeutics have?
Each share of Brainstorm Cell Therapeutics has $0.00 of cash and investments, as of June 30, 2026.
Has Brainstorm Cell Therapeutics bought back shares?
Brainstorm Cell Therapeutics’s share count rose about 1636% from 2011 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.